Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

In the United States, patients with renal cell carcinoma are more likely to die from COPD than the general population. Chronic obstructive pulmonary disease (COPD) is a major cause of death among ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

The findings underscore the critical role of tumor size reduction in improving survival outcomes for patients with advanced renal cell carcinoma (aRCC). The latest analysis, presented Feb. 13-14 ...